We will recruit, screen, and enroll 50 HIV-seropositive individuals into an outpatient, prospective, stratified, randomized, double-blind, multi-site phase II trail of Peptide T vs. placebo. Patients will have moderate cognitive deficiency and CD4 cell count less than 500. Phase I studies suggested a possible beneficial effect of peptide T on certain cognitive processes in HIV patients, raising the possibility that it may potentially reverse existing moderate to severe cognitive impairments that often accompany HIV infection.
Showing the most recent 10 out of 38 publications